Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Juvenile Idiopathic Arthritis: An Idea Whose Time Has Gone?Journal of Rheumatology.  46:124-126. 2019
2018 Clinical Characteristics and Factors Associated With Disability and Impaired Quality of Life in Children With Juvenile Systemic Sclerosis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.Arthritis Care and Research.  70:1806-1813. 2018
2018 Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature.Pediatric Rheumatology.  16:71. 2018
2018 Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.Arthritis and Rheumatology2018
2018 Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population.JAMA Internal Medicine.  178:1224-1229. 2018
2018 Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease.Arthritis and Rheumatology.  70:1508-1518. 2018
2018 Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis.Pediatric Clinics of North America.  65:657-674. 2018
2018 Risk Factors for Intraarticular Heterotopic Bone Formation in the Temporomandibular Joint in Juvenile Idiopathic Arthritis.Journal of Rheumatology.  45:1301-1307. 2018
2018 Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.Annals of the Rheumatic Diseases.  77:1012-1016. 2018
2018 Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label StudyArthritis and Rheumatology.  70:1144-1154. 2018
2018 Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).Clinical Trials.  15:268-277. 2018
2018 Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis.Arthritis Care and Research2018
2018 High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.Arthritis and Rheumatology.  70:594-605. 2018
2018 Adiposity in Juvenile Psoriatic Arthritis.Journal of Rheumatology.  45:411-418. 2018
2018 Delays to Care in Pediatric Lupus Patients: Data From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.Arthritis Care and Research.  70:420-427. 2018
2018 Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.Journal of Rheumatology.  45:107-114. 2018
2018 The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United StatesJournal of Scleroderma and Related Disorders2018
2017 Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.Journal of Rheumatology.  44:1884-1888. 2017
2017 Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.Pediatric Rheumatology.  15:79. 2017
2017 Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease Outcomes.Arthritis Care and Research.  69:1617-1619. 2017
2017 Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease.Journal of Pediatrics.  189:31-39. 2017
2017 Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.Arthritis and Rheumatology.  69:1733-1740. 2017
2017 Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis.Pediatric Rheumatology.  15:52. 2017
2017 Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches.Arthritis Research.  19:84. 2017
2017 Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.Journal of Pediatrics.  184:38-44.e1. 2017
2017 A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities.Pediatric Rheumatology.  15:31. 2017
2017 The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.Pediatric Rheumatology.  15:30. 2017
2017 Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.Pediatric Rheumatology.  15:23. 2017
2017 Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.Journal of Rheumatology.  44:352-360. 2017
2016 Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.BMC Musculoskeletal Disorders.  17:405. 2016
2016 The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.Arthritis Research.  18:210. 2016
2016 Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients.Pediatric Rheumatology.  14:49. 2016
2016 The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.Journal of Rheumatology.  43:1755-1762. 2016
2016 Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis.Arthritis Care and Research.  68:1803-1811. 2016
2016 A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.Journal of Immunology.  196:2492-2503. 2016
2016 Familial autoimmunity in the Childhood Arthritis and Rheumatology Research Alliance registry.Pediatric Rheumatology.  14:14. 2016
2016 Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer.JAMA Dermatology.  152:164-172. 2016
2016 Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.Arthritis and Rheumatology.  68:56-66. 2016
2015 Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis.Journal of Rheumatology.  42:2155-2159. 2015
2015 Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Annals of the Rheumatic Diseases.  74:1065-1071. 2015
2015 Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.Arthritis Care and Research.  67:624-632. 2015
2015 Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.Arthritis Care and Research.  67:731-736. 2015
2015 Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project.Arthritis Care and Research.  67:529-537. 2015
2015 Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.Journal of Rheumatology.  42:541-546. 2015
2014 Development and retrospective validation of the juvenile spondyloarthritis disease activity index.Arthritis Care and Research.  66:1775-1782. 2014
2014 Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.Annals of the Rheumatic Diseases.  73:1942-1948. 2014
2014 Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.Arthritis Care and Research.  66:1604-1611. 2014
2014 Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.Journal of Rheumatology.  41:2078-2084. 2014
2014 Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al.Arthritis Care and Research.  66:1430-1431. 2014
2014 Risk of malignancy associated with biologic agents in pediatric rheumatic disease.Current Opinion in Rheumatology.  26:538-542. 2014
2014 Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.Journal of Rheumatology.  41:113-118. 2014
2014 Imaging of the temporomandibular joint in juvenile idiopathic arthritis.Arthritis Care and Research.  66:47-54. 2014
2014 Treatment advances in systemic juvenile idiopathic arthritis.F1000prime reports.  6:21. 2014
2013 Using registries to identify adverse events in rheumatic diseases.Pediatrics.  132:e1384-e1394. 2013
2013 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.Arthritis and Rheumatism.  65:2499-2512. 2013
2013 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.Arthritis Care and Research.  65:1551-1563. 2013
2013 High doses of infliximab in the management of juvenile idiopathic arthritis.Journal of Rheumatology.  40:1749-1755. 2013
2013 Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report.Pediatric Rheumatology.  11:25. 2013
2013 Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.Journal of Rheumatology.  40:936-942. 2013
2013 Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.Arthritis and Rheumatism.  65:1384-1389. 2013
2013 Infectious complications in juvenile idiopathic arthritis.Current Rheumatology Reports.  15:327. 2013
2013 Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.Journal of the American Medical Association.  309:887-895. 2013
2013 What is the background incidence of malignancy in children with rheumatic disease?Current Rheumatology Reports.  15:310. 2013
2013 Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.American Journal of Ophthalmology.  155:183-189.e1. 2013
2013 Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.Arthritis and Rheumatism.  65:48-58. 2013
2012 Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry.Journal of Rheumatology.  39:2341-2351. 2012
2012 Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.Controlled Clinical Trials.  33:1211-1216. 2012
2012 Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.Arthritis Care and Research.  64:1480-1489. 2012
2012 Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.Journal of Rheumatology.  39:1867-1874. 2012
2012 Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis.Journal of Rheumatology.  39:1880-1887. 2012
2012 Sarcoidosis in a young child with Alagille syndrome: a case report.Pediatric Rheumatology.  10:32. 2012
2012 Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis.Journal of Oral and Maxillofacial Surgery.  70:1802-1807. 2012
2012 Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:2773-2780. 2012
2012 Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis.Arthritis Care and Research.  64:1001-1010. 2012
2012 Back mobility and interincisor distance ranges in racially diverse North American healthy children and relationship to generalized hypermobility.Pediatric Rheumatology.  10:17. 2012
2012 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care and Research.  64:625-639. 2012
2012 Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.Arthritis Care and Research.  64:612-615. 2012
2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
2011 Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Journal of the American Medical Association.  306:2331-2339. 2011
2011 Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.Journal of Rheumatology.  38:2675-2681. 2011
2011 Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.Pharmacoepidemiology and Drug Safety.  20:1199-1209. 2011
2011 Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjogren's syndrome.Journal of Clinical Endocrinology and Metabolism.  96:3302-3307. 2011
2011 Temporomandibular joint arthritis in pediatric sjogren disease and sarcoidosis.Journal of Rheumatology.  38:2272-2273. 2011
2011 Geographic distribution of endemic fungal infections among older persons, United States.Emerging Infectious Diseases.  17:1664-1669. 2011
2011 ReplyArthritis Care and Research.  63:1355. 2011
2011 ReplyArthritis Care and Research.  63:1353. 2011
2011 High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort.Pediatric Rheumatology.  9:20. 2011
2011 The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.Annals of the Rheumatic Diseases.  70:1401-1406. 2011
2011 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Arthritis Care and Research.  63:465-482. 2011
2011 Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series.Journal of Rheumatology.  38:180-181. 2011
2011 Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis.Arthritis Care and Research.  63:10-16. 2011
2010 Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.Osteoporosis International.  21:1573-1584. 2010
2010 Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?Pediatric Rheumatology.  8:23. 2010
2010 Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis.Arthritis and Rheumatism.  62:2499-2509. 2010
2010 Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.Annals of the Rheumatic Diseases.  69:43-47. 2010
2009 Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura.Journal of Pediatrics.  155:136-139. 2009
2008 Optimal treatment of knee monarthritis in juvenile idiopathic arthritis: a decision analysis.Arthritis and Rheumatism.  59:1580-1588. 2008
2008 Usage of intra-articular corticosteroid injections for the treatment of juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada.Clinical and Experimental Rheumatology.  26:700-703. 2008
2008 Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).Journal of Rheumatology.  35:343-348. 2008
2007 Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada.Journal of Rheumatology.  34:1918-1924. 2007
2007 Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis.Pediatric Radiology.  37:544-548. 2007
2007 Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.Journal of Rheumatology.  34:1133-1138. 2007
2007 Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software.Journal of Rheumatology.  34:234. 2007
2006 Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis.Journal of Rheumatology.  33:2330-2336. 2006

Chapter

Year Title Altmetric
2012 Juvenile idiopathic arthritis.  637-647. 2012

Principal Investigator On

  • GEF (General Endowment Fund) - Scholar  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2007 - 2020
  • Observational Study of Pediatric Rheumatic Diseases : The CARRA Registry  awarded by Duke University 2015 - 2018
  • CARRA Registry Leadership  awarded by CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE (CARRA) 2014 - 2018
  • Patients, Advocates and Rheumatology Teams Network for Research and Service (PARTNERS) - Phase II  awarded by DUKE CLINICAL RESEARCH INSTITUTE 2015 - 2017
  • Sequence of Medication Use in JIA  awarded by CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE (CARRA) 2016 - 2017
  • CARRA Steering Committee  awarded by CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE (CARRA) 2015 - 2016
  • Childhood Arthritis and Rheumatology Research Alliance ("CARRA Registry")  awarded by Duke University 2012 - 2015
  • Patients, Advocates and Rheumatology Teams Network for Research and Service (PARTNERS) Consortium  awarded by DUKE CLINICAL RESEARCH INSTITUTE 2014 - 2015
  • The Effectiveness of Methotrexate to Prevent Extension of Early Limited JIA  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2014 - 2015
  • Childhood Arthritis and Research Alliance Network (CARRANet): Juvenile Dermatomyositis Consensus Treatment Plan  awarded by DUKE CLINICAL RESEARCH INSTITUTE 2013 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2015
  • CARRA Administrative Core  awarded by Duke University 2014
  • Comparative Effectiveness of Therapy for Enthesitis-Related Arthritis  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA) 2012 - 2014
  • Childhood Arthritis and Research Alliance Network (CARRANet): Juvenile Idiopathic Arthritis Consensus Treatment Plan  awarded by Duke University 2013 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2013
  • Improved Understanding of the Biology and use of TNF Inhibition in Children with JIA  awarded by CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI) 2011 - 2013
  • CARRA Registry  awarded by Duke University 2010 - 2012
  • CARRA Enhanced Drug Safety Surveillance Project  awarded by CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER 2008 - 2012
  • JIA Treatment Guidelines  awarded by American College of Rheumatology 2009 - 2010
  • Full Name

  • Timothy Beukelman
  • Blazerid

  • beukelma